Business
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's first-in-class commercial portfolio alongside INGREZZA® (valbenazine) and CRENESSITY® (
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Adds recently launched therapy with strong early adoption and meaningful commercial potential","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":239,"olType":false},{"type":"text","content":"SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's first-in-class commercial portfolio alongside INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont).","length":567,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmdenVtXM7LFmbrt7BNiag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMA--/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/VXAHrYaJytBIFI3r1gsowA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTExOA--/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74}},"href":"https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Today marks an important advancement in Neurocrine's mission to deliver life-changing treatments for patients with significant unmet needs," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. "We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community, and we look forward to working together to make...